Metraipolis › archive › dc_b2ac8e298dba
Cost-effectiveness analysis of lurbinectedin plus atezolizumab as first-line treatment for extensive-stage small-cell lung cancer — Europe PMC PMID:41063984
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41063984
- DOI
- 10.3389/fimmu.2025.1658740
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T19:34:39.878Z
- SHA-256 of the archived text
28646b9b31a71f1b4a123925abdd550c40d47bc5d30007b49709d6c0f0ba2a0d- Stable URL of this page
https://metraipolis.com/documento/dc_b2ac8e298dba
How to cite
Cost-effectiveness analysis of lurbinectedin plus atezolizumab as first-line treatment for extensive-stage small-cell lung cancer — Europe PMC PMID:41063984 — Europe PMC (en), https://europepmc.org/article/MED/41063984 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b2ac8e298dba (Metraipolis archive dc_b2ac8e298dba, sha256 28646b9b31a71f1b4a123925abdd550c40d47bc5d30007b49709d6c0f0ba2a0d)
BibTeX
@misc{dcb2ac8e298dba,
title = {Cost-effectiveness analysis of lurbinectedin plus atezolizumab as first-line treatment for extensive-stage small-cell lung cancer — Europe PMC PMID:41063984},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41063984},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b2ac8e298dba; sha256 28646b9b31a71f1b4a123925abdd550c40d47bc5d30007b49709d6c0f0ba2a0d},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41063984. Agents can read the archived copy with the MCP tool read_document.